Our Company

About 60° Pharmaceuticals

Our company history and mission

60° Pharmaceuticals (60P) was founded in 2010 with a mission to realize new ways to improve and extend people’s lives by discovering, developing, and distributing new best-in-class medicines for the treatment and prevention of tropical diseases. The Company is now developing and commercializing products more broadly for infectious disease.


We apply the same passion, energy, and culture of innovation that allowed the successful approval of ARAKODA® (tafenoquine) to making a difference in the world. We are committed to finding the tools and strategies that will help us overcome some of the planet’s greatest health challenges.

Return for investors

Our core business is delivering infectious disease drug development and commercialization while providing an attractive ROI.

Our collaborative approach

60P has embraced an open innovation approach to reduce the time, cost, and risk needed to build a portfolio of drug discovery and development projects. We collaborate with leading research institutions to discover and develop medicines for infectious diseases.

Our vision

Our intention is to become the trusted leader in changing the practice of malaria prevention and forging new weapons to combat life-threatening infectious diseases.


Headquarters: Washington, DC (USA)

Research & Development: Australia

Executive Committee

Geoffrey Dow, Chief Executive and President

As a co-founder and CEO of 60P, Dr. Geoffrey Dow brings more than 20 years of product development expertise in tropical diseases and has an extensive publication and patent history. His decades of hands-on experience include 13 years in key leadership and advisory roles in the antimalarial drug development program at the Walter Reed Army Institute of Research and at the U.S. Army Medical Materiel Development Activity.


At 60P, Geoff is integrally involved in management of the tafenoquine development program. He was awarded a PhD in Veterinary and Biomedical Sciences by Murdoch University, Australia, and received his MBA from the University of Maryland, USA. As an inventor and contributor on eight patent applications, Geoff’s ultimate goal is the discovery, development, and regulatory approval of one or more drugs for a tropical disease.

Tyrone Miller, Chief Financial Officer and Director

Beyond managing 60P’s accounting and tax issues, Ty leverages his 15 years of CPA experience across the public and private sectors to interact with government, nonprofit, and corporate partners regarding matters of market entry, due diligence, and investment-related decisions.


Prior to joining 60P, Ty established a proprietary tax and accounting practice, Miller Tax Advisory, where he is the principal. Ty earned a BBA at Emory University, Atlanta, Georgia, USA, and obtained his CPA license in Maryland.

Bryan Smith, Chief Medical Officer

With over 20 years of medical experience, including six years as the Product Manager of antimalarial drugs for the U.S. Army Medical Materiel Development Activity, Bryan brings a valuable skill set to 60P. He has held many positions and ranks during his career—including director at the Clinical Trials Center, Department of Immunology and Medicine; research physician at the Department of Enteric Diseases; principal medical consultant at Clinical Network Services; and U.S. Army colonel and force surgeon.


His very strong academic background is punctuated by 16 publications since 2004. He completed his Doctor of Medicine from Uniformed Services University of the Health Sciences in 1992.

Jennifer Herz, Director

As 60P’s head consultant, Jennifer brings over 20 years of commercial, business development, and scientific affairs experience in the bio-pharma industry. Her background is very vaccine focused. As the first Managing Director of Sanofi Pasteur in Australia, she developed the company into a major provider of vaccines in Australia, commercially launching five new vaccines. She was also the founding Chair of the Medicines Australia Vaccine Industry Group and served on the Board of Medicines Australia.


Her concurrent position is as managing director at Biointelect Pty. Ltd., a life science consulting organization. Jennifer previously held the position of Senior Director at Astra Zeneca Europe.


Since 2007, Jennifer has worked as a consultant in both Europe and Australia to both biotech companies and multinational pharmaceutical companies, assisting with strategic planning, market access, public affairs, medical, regulatory and scientific affairs, and training.

FORWARD LOOKING STATEMENTS: This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, ARAKODA, and expectations regarding our pipeline, including trial design and development timelines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: uncertainty around and costs associated with the development of ARAKODA as a potential treatment for COVID-19 and our other product candidates; dependence on management, directors and other key personnel; the impact of the COVID-19 pandemic on our business; our need for substantial additional funding; our dependence on the success of our most advanced product candidates; risks related to the regulatory approval process; risks associated with the clinical development process and reliance on interim or topline clinical trial results; risks related to healthcare laws and other legal compliance matters; risks related to potential commercialization; risks related to manufacturing and our dependence on third parties; risks relating to intellectual property; our ability to maintain effective internal control over financial reporting and the significant costs as a result of operating as a company. These important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Cases and 1 Million deaths in the U.S. from COVID-19 infections


Annual deaths from malaria globally


Travelers to endemic regions per annum


Dengue infections per year


1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036